STOCK TITAN

CRESCITA THERAPEUTICS ORD - $CRRTF STOCK NEWS

Welcome to our dedicated page for CRESCITA THERAPEUTICS ORD news (Ticker: $CRRTF), a resource for investors and traders seeking the latest updates and insights on CRESCITA THERAPEUTICS ORD stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CRESCITA THERAPEUTICS ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CRESCITA THERAPEUTICS ORD's position in the market.

Rhea-AI Summary
Crescita Therapeutics Inc. reported financial results for Q4-2023 and F2023, with revenue and gross profit decreasing compared to the previous year. The company's adjusted EBITDA also declined significantly. Despite challenges in the manufacturing segment, the skincare business showed growth and new partnerships are being pursued.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) reported Q3-2023 financial results, including a revenue decrease of $2,999, termination of an agreement with Taro Pharmaceuticals, and a decrease in manufacturing revenue. The company also announced a normal course issuer bid and the relaunch of Alyria as a direct-to-consumer brand. Despite challenges, the skincare business saw a 44% increase in revenue, and ART FILLER is gaining momentum in the Canadian market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.26%
Tags
-
Rhea-AI Summary
Crescita Therapeutics approved for normal course issuer bid to purchase up to 10% of its public float, management believes current market price may not reflect underlying value of the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.04%
Tags
none
CRESCITA THERAPEUTICS ORD

OTC:CRRTF

CRRTF Rankings

CRRTF Stock Data

6.25M
17.16M
10.35%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
Laval